Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
NCT04561362Phase 2Active, not recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Jul 2020
- Primary completion
- Jan 2027
- Modality
- Cyclic Peptides, Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates
- Countries
- 6
01
Overview
Phase 2, open-label trial of zelenectide pevedotin in urothelial carcinoma (UC), triple-negative breast cancer (TNBC), breast cancer and 3 more (13 arms), sponsored by Bicycle Therapeutics. Primary endpoints: Treatment Emergent Adverse Events up to 1 year, Dose Limiting Toxicities at 28 days and 5 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
zelenectide pevedotin
03
Conditions
urothelial carcinoma (UC)triple-negative breast cancer (TNBC)breast cancernon-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT04561362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561362.